CareDx (NASDAQ:CDNA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

Several other brokerages have also recently weighed in on CDNA. HC Wainwright set a $12.00 price target on shares of CareDx and gave the stock a “buy” rating in a research note on Thursday, April 12th. ValuEngine cut shares of CareDx from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Zacks Investment Research cut shares of CareDx from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Finally, TheStreet upgraded shares of CareDx from a “d-” rating to a “c-” rating in a research note on Tuesday, April 10th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $8.65.

Shares of CareDx stock opened at $9.20 on Friday. CareDx has a 1-year low of $0.76 and a 1-year high of $9.29. The company has a current ratio of 0.62, a quick ratio of 0.50 and a debt-to-equity ratio of -3.08.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, March 22nd. The company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.05. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $12.09 million. CareDx had a negative net margin of 114.79% and a negative return on equity of 349.65%. sell-side analysts forecast that CareDx will post -0.43 earnings per share for the current year.

In other news, insider Peter Maag sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 27th. The shares were sold at an average price of $7.87, for a total transaction of $118,050.00. Following the sale, the insider now directly owns 272,037 shares in the company, valued at approximately $2,140,931.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. raised its position in shares of CareDx by 125.5% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 64,426 shares of the company’s stock valued at $473,000 after purchasing an additional 35,851 shares during the period. Park West Asset Management LLC bought a new stake in shares of CareDx during the 4th quarter valued at $5,944,000. Macquarie Group Ltd. bought a new stake in shares of CareDx during the 4th quarter valued at $190,000. Millennium Management LLC bought a new stake in shares of CareDx during the 4th quarter valued at $336,000. Finally, Ardsley Advisory Partners bought a new stake in shares of CareDx during the 4th quarter valued at $147,000. Hedge funds and other institutional investors own 51.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “CareDx (CDNA) Upgraded at BidaskClub” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/04/22/caredx-cdna-upgraded-at-bidaskclub.html.

About CareDx

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.